Spotlight On: Much needed momentum for Sanofi?
In a week of major new drug approvals, one company arguably has more to gain than its competitors. Last Tuesday, the FDA approved Dupixent, a first-in-class treatment for moderate-to-severe atopic dermatitis; the latest product to emerge from Regeneron and Sanofi’s R&D pact. Regeneron is widely acknowledged as the heavy lifter on innovation in this relationship, while Sanofi provides much of the financial muscle. The French company is now desperate for a return on its investment.